Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Sable Bio logo — Empowering Discovery: Precision Insights for Safer Drug Targ...

Sable Bio

Empowering Discovery: Precision Insights for Safer Drug Targets.

Founded 2023 United Kingdom London, United Kingdom 15 employees Seed Total: $4.24M AI, Biotechnology +2

General Information

Company Name Sable Bio
Founded Year 2023
Location United Kingdom London, United Kingdom
Employees 15
Industries AI, Biotechnology, Pharmaceutical +1
Funding Stage Seed
Business Model B2B, SaaS, DaaS
Revenue Model Subscription, Usage Based, Service Fee
Offices as of Sep 2026
London, United Kingdom
Social

BounceWatch is an independent company data service, not affiliated with Sable Bio. To contact Sable Bio, visit sablebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Sable Bio compare?

A PDF of Sable Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Sable Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Sable Bio

Sable Bio, founded in 2023, is a UK-based innovator at the nexus of AI, Biotechnology, and Privacy and Security. The company is committed to transforming drug development with its pioneering approach to predicting drug safety, thereby minimizing trial failures and optimizing patient outcomes. Their tagline, "Empowering Discovery: Precision Insights for Safer Drug Targets," encapsulates their mission to provide precision insights that enhance the drug development process.

With a recent €10.00M seed investment secured on 14 April 2026 from notable investors such as BoxGroup, Redalpine, Frst, Gradient, Aidan Gomez, Clement Delangue, and Mario Goetze, Sable Bio is positioned for impactful growth. Its data-driven methodology in assessing clinical side effects emphasizes enhanced validation strategies and risk reduction. This financial backing underscores investor confidence in Sable Bio's innovative capabilities and potential to reshape the biotech industry.

Business keywords: Drug Safety Prediction, Clinical Side Effects Assessment, Drug Development Optimization, Data-Driven Drug Development, AI in Biomedical Data Analysis, Target Safety Insights, Assay Validation Strategies, Risk Minimization in Drug Development, Toxicity Testing, Biopharmaceutical Data Solutions, Advanced Workflows, Healthcare Data Analytics, Biomedical Data Insights, Pharmaceutical Validation

Services & Products

AI-driven toxicology analysis platform
Unified safety data management
Risk prioritization and mitigation

Target Customers

toxicologists pharmaceutical companies biotech firms safety teams

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed £2.74M 3
Episode 1 Ventures MMC Ventures Seedcamp
Episode 1 Ventures, MMC Ventures +1
01 Feb 2026
Seed £1.50M 2
Episode 1 Ventures Seedcamp
Episode 1 Ventures, Seedcamp
01 Feb 2024

Latest News

View All
Magnitude Biosciences secures €1.5 million investment to scale in-vivo drug discovery platform — Eu-startups
Magnitude Biosciences secures €1.5 million investment to scale in-vivo drug discovery platform
Eu-startups Sep 15, 2026
UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform — Eu-startups
UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform
Eu-startups Sep 02, 2026
Swiss BioTech startup ALP Bio raises €1.9 million to advance immune organoid and AI platform — Eu-startups
Swiss BioTech startup ALP Bio raises €1.9 million to advance immune organoid and AI platform
Eu-startups Apr 30, 2026
With pharma R&D teams under pressure to turn AI into usable science, Helical lands €8.4 million — Eu-startups
With pharma R&D teams under pressure to turn AI into usable science, Helical lands €8.4 million
Eu-startups Apr 14, 2026
Ternary Therapeutics targets “undruggable” proteins with AI-designed molecular glues, raising €4.1 m... — Eu-startups
Ternary Therapeutics targets “undruggable” proteins with AI-designed molecular glues, raising €4.1 million
Eu-startups Mar 16, 2026
UK AI drug safety startup Sable Bio raises €3.15 million; plans to grow its London team — Eu-startups
UK AI drug safety startup Sable Bio raises €3.15 million; plans to grow its London team
Eu-startups Feb 11, 2026

Sable Bio Alternatives & Competitors

View All Alternatives
Sable Bio vs
Intelligencia AI
Intelligencia AI United States

Applying machine learning in drug development

Series A
112 employees
AI, Big Data
Sable Bio vs
Ignota Labs
Ignota Labs United Kingdom

Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hop...

Seed
23 employees
AI, Biotechnology
Sable Bio vs
AsedaSciences®
AsedaSciences® Switzerland

Helping scientists develop safer chemicals

11 employees
Biotechnology, Life Sciences
Also compare with: Sable Bio vs Partex.AI Technology Partex.AI Technology View all alternatives

FAQ About Sable Bio

Empowering Discovery: Precision Insights for Safer Drug Targets.
Sable Bio was founded in 2023.
Sable Bio is headquartered in London, United Kingdom.
Sable Bio operates in AI, Biotechnology, Pharmaceutical and Privacy and Security. Its work centres on Drug Safety Prediction, Clinical Side Effects Assessment, Drug Development Optimization and Data-Driven Drug Development. Its customers include toxicologists, pharmaceutical companies and biotech firms.
Sable Bio has a B2B, SaaS and DaaS business model. Its revenue comes from Subscription, Usage Based and Service Fee.
Sable Bio has approximately 15 employees.
Sable Bio has completed 2 funding rounds, raising a total of $4.24M. The latest funding stage is Seed.
Sable Bio offers: AI-driven toxicology analysis platform, Unified safety data management, Risk prioritization and mitigation.
Top alternatives and competitors to Sable Bio include Intelligencia AI, Ignota Labs, AsedaSciences®, AIGEN Sciences Inc., Ozette. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sable Bio and Intelligencia AI are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Sable Bio, https://bouncewatch.com/company/sable-bio, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes